【摘要】 新型冠状病毒诱导的原发免疫性血小板减少症(SARS-CoV-2-induced ITP)是一种继发于病毒感染的自身免疫性疾病。该病主要通过排除法诊断，需检测凝血四项、血小板生成素、药物依赖性抗体等指标，与其他导致血小板数降低的诱因鉴别后谨慎诊断。如何平衡出血与血栓风险，制定个体化给药方案是该病治疗的重点与难点。由于血小板生成素受体激动剂(TPO-RA)存在加速血栓形成的副作用，可能加重患者肺栓塞症状，因此仅用于难治性SARS-CoV-2-induced ITP患者。本文就SARS-CoV-2-induced ITP的发病机制、诊断及治疗方案的最新研究进展作一综述。更多还原

【Abstract】 SARS-CoV-2-induced immune thrombocytopenia(SARS-CoV-2-induced ITP) is an autoimmune disease secondary to virus infections.Its diagnosis is often based on exclusion of other possible causes of thrombocytopenia in COVID-19 patients.Common laboratory examinations include coagulation function,thrombopoietin and drug-dependent antibodies.Since both bleeding and thrombosis risks are seen in SARS-CoV-2-induced ITP patients,individual remedy is essential for the treatment of this disease.Because thrombopoietin receptor agonist(TPO-RA) has the side effect of accelerating thrombosis and may aggravate the pulmonary embolism symptoms of patients,it should be used for refractory SARS-CoV-2-induced ITP patients only.This review briefly summarizes the recent research progress in the pathogenesis,diagno sis and treatment of SARS-CoV-2-induced ITP.更多还原